At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 4,017 enrolled
Drug / intervention
Dapagliflozin +1 moredrug
Likely dose
Dapagliflozin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on Cardiometabolic Outcomes in Patients Without Diabetes With Acute Myocardial Infarction at Increased Risk for Subsequent Development of Heart Failure
In Brief
A Phase 3 clinical trial evaluating Dapagliflozin and Placebo for Acute Myocardial Infarction and Heart Failure. Completed, enrolled 4,017 participants across 103 sites in 2 countries.
Detailed Summary
This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for hospitalisation for heart failure (HHF), cardiovascular (CV) death, and other cardiometabolic outcomes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myocardial Infarction, Heart Failure
CountriesSweden, United Kingdom
CollaboratorsUppsala University
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartDec 2020
Primary CompletionJul 2023
TodayJul 2026
First PostedSep 25, 2020
Enrollment StartDec 22, 2020
Primary CompletionJul 5, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.8 years ago
Interventions
Dapagliflozindrug
Dapagliflozin 10 mg tablets given once daily, per oral use
Placebodrug
Placebo matching dapagliflozin 10 mg tablets given once daily, per oral use